Lynparza Tablets 150 mg (リムパーザ錠150mg)

Country: Japan

Language: English

Source: すりの適正使用協議会 RAD-AR Council, Japan

Active ingredient:

Olaparib

Available from:

AstraZeneca K.K

INN (International Name):

Olaparib

Pharmaceutical form:

green to grayish green tablet, major axis: approx. 14.7 mm, minor axis: approx. 7.6 mm, thickness: approx. 6.8 mm

Product summary:

Print on wrapping: OP150、リムパーザ150mg、Lynparza150mg

Patient Information leaflet

Drug Information Sheet("Kusuri-no-Shiori")
Internal
Revised: 09/2023
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
LYNPARZA TABLETS 150 MG
ACTIVE INGREDIENT:
Olaparib
DOSAGE FORM:
green to grayish green tablet, major axis: approx. 14.7 mm,
minor axis: approx. 7.6 mm, thickness: approx. 6.8 mm
IMPRINT OR PRINT ON WRAPPING:
OP150、リムパーザ 150mg、Lynparza150mg
EFFECTS OF THIS MEDICINE
This medicine suppresses proliferation of tumor cells by inhibiting
the function of PARP
enzymes, which restore damaged DNA.
It is usually used for maintenance treatment in patients with
platinum-sensitive recurrent
ovarian cancer, for maintenance treatment after first line
chemotherapy in patients with
BRCA-mutated ovarian cancer, for maintenance treatment after first
line chemotherapy
containing bevacizumab in patients with homologous recombination
repair deficient ovarian
cancer, in patients with unresectable or recurrent BRCA-mutated HER2
negative breast cancer
with prior anticancer chemotherapy, for adjuvant treatment in patients
with BRCA-mutated
HER2 negative breast cancer at high risk of recurrence, in patients
with BRCA-mutated
castrate-resistant prostate cancer with distant metastasis, or for
maintenance treatment after
platinum-based chemotherapy in patients with BRCA-mutated curatively
unresectable
pancreas cancer.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have liver dysfunction or renal dysfunction.
・If you are pregnant or breastfeeding.
・If you are taking any other m